Abstract:ABSTRACT Flavivirus infection capitalizes on cellular lipid metabolism to remodel the cellular intima, creating a specialized lipid environment conducive to viral replication, assembly, and release. The Japanese encephalitis virus (JEV), a member of the Flavivirus genus, is responsible for significant morbidity and mortality in both humans and animals. Currently, there are no effective antiviral drugs available to combat JEV infection. In this study, we embarked on a quest to identify anti-JEV compounds within a lipid compound library. Our research led to the discovery of two novel compounds, isobavachalcone (IBC) and corosolic acid (CA), which exhibit dose-dependent inhibition of JEV proliferation. Time-of-addition assays indicated that IBC and CA predominantly target the late stage of the viral replication cycle. Mechanistically, JEV nonstructural proteins 1 and 2A (NS1 and NS2A) impede 5′-adenosine monophosphate (AMP)-activated protein kinase (AMPK) activation by obstructing the liver kinase B1 (LKB1)–AMPK interaction, resulting in decreased p-AMPK expression and a consequent upsurge in lipid synthesis. In contrast, IBC and CA may stimulate AMPK by binding to its active allosteric site, thereby inhibiting lipid synthesis essential for JEV replication and ultimately curtailing viral infection. Most importantly, in vivo experiments demonstrated that IBC and CA protected mice from JEV-induced mortality, significantly reducing viral loads in the brain and mitigating histopathological alterations. Overall, IBC and CA demonstrate significant potential as effective anti-JEV agents by precisely targeting AMPK-associated signaling pathways. These findings open new therapeutic avenues for addressing infections caused by Flaviviruses. IMPORTANCE This study is the inaugural utilization of a lipid compound library in antiviral drug screening. Two lipid compounds, isobavachalcone (IBC) and corosolic acid (CA), emerged from the screening, exhibiting substantial inhibitory effects on the Japanese encephalitis virus (JEV) proliferation in vitro . In vivo experiments underscored their efficacy, with IBC and CA reducing viral loads in the brain and mitigating JEV-induced histopathological changes, effectively shielding mice from fatal JEV infection. Intriguingly, IBC and CA may activate 5′-adenosine monophosphate (AMP)-activated protein kinase (AMPK) by binding to its active site, curtailing the synthesis of lipid substances, and thus suppressing JEV proliferation. This indicates AMPK as a potential antiviral target. Remarkably, IBC and CA demonstrated suppression of multiple viruses, including Flaviviruses (JEV and Zika virus), porcine herpesvirus (pseudorabies virus), and coronaviruses (porcine deltacoronavirus and porcine epidemic diarrhea virus), suggesting their potential as broad-spectrum antiviral agents. These findings shed new light on the potential applications of these compounds in antiviral research.

Identification Of Three Antiviral Inhibitors Against Japanese Encephalitis Virus From Library Of Pharmacologically Active Compounds 1280

Structure-based Discovery of Two Antiviral Inhibitors Targeting the NS3 Helicase of Japanese Encephalitis Virus

Screening of FDA-Approved Drugs for Inhibitors against Japanese Encephalitis Virus Infection.

[Method for Japanese Encephalitis Virus NS3 Protease Activity Analysis and High-Throughput Screening Assay for Inhibitors].

Screening of Natural Extracts for Inhibitors Against Japanese Encephalitis Virus Infection

Generation and characterization of Japanese encephalitis virus expressing GFP reporter gene for high throughput drug screening

Screening a neurotransmitter-receptor-related inhibitor library identifies clomipramine HCl as a potential antiviral compound against Japanese encephalitis virus

Novel antiviral discoveries for Japanese encephalitis virus infections through reporter virus‐based high‐throughput screening

Peptide Inhibitor of Japanese Encephalitis Virus Infection Targeting Envelope Protein Domain Iii

Effective Inhibition of Japanese Encephalitis Virus Replication by Shrnas Targeting Various Viral Genes in Vitro and in Vivo.

Structure-based Discovery of Antiviral Inhibitors Targeting the E Dimer Interface of Japanese Encephalitis Virus.

Two novel compounds inhibit Flavivirus infection in vitro and in vivo by targeting lipid metabolism

Antiviral Activity of Phage Display-Selected Peptides Against Japanese Encephalitis Virus Infection in Vitro and in Vivo.

In Vitro Inhibition of Japanese Encephalitis Virus Replication by Capsid-Targeted Virus Inactivation

Rna Interference Screening Reveals Requirement For Platelet-Derived Growth Factor Receptor Beta In Japanese Encephalitis Virus Infection

Adenosyl derivatives as a potential inhibitors of NS3 protease of Japanese encephalitis virus (JEV): In silico molecular insight into therapeutic discovery

Molecular interaction of the antiviral compound CW-33 and its analogues with the NS2B-NS3 protease of the Japanese encephalitis virus

Inhibition of Japanese Encephalitis Virus Entry into the Cells by the Envelope Glycoprotein Domain Iii (ediii) and the Loop3 Peptide Derived from Ediii

Recent Advances in Antivirals for Japanese Encephalitis Virus

Natural products and derivatives as Japanese encephalitis virus antivirals

Structural basis for neutralization of Japanese encephalitis virus by two potent therapeutic antibodies